Paul Sax, MD
May 23rd, 2012
Panel: Azithromycin and Cardiovascular Risk
Paul Sax, MD, Joseph S. Ross, MD, MHS and Jeffrey Lance Anderson, MD
Three experts offer perspective on a large database study showing an association between azitrhromycin use and increased risk for cardiovascular death.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?